Prostate cancer treatment ranges from careful monitoring with no immediate intervention to surgery, radiation, hormone therapy, and chemotherapy, depending on how aggressive the cancer is and whether it has spread. The good news: when caught before it spreads beyond the prostate or nearby lymph nodes, the five-year survival rate is effectively 100%. Even for cancers that have metastasized to distant parts of the body, the five-year survival rate is about 40%, and treatment options continue to expand. The path forward depends on your specific risk category, your age, and how the cancer is likely to affect your daily life.
When Treatment Means Watching Carefully
Not all prostate cancers need immediate treatment. For low-risk, slow-growing tumors, active surveillance is often the recommended first step. This applies mainly to cancers with a Gleason score of 6 (graded 3+3), and it can also be an option for some men with a Gleason score of 7 (graded 3+4). The Gleason score describes how abnormal the cancer cells look under a microscope, and lower scores indicate slower-growing disease that may never cause symptoms in your lifetime.
Active surveillance isn’t the same as ignoring the cancer. It involves PSA blood tests every three to six months and a confirmatory biopsy within 6 to 24 months of diagnosis to make sure the cancer remains low-risk. If follow-up testing shows the cancer is becoming more aggressive, you and your doctor shift to active treatment. The goal is to avoid the side effects of surgery or radiation for cancers that may never pose a real threat, while catching any changes early enough to treat effectively.
Surgery: What It Involves and What to Expect
A radical prostatectomy removes the entire prostate gland and is one of the most common treatments for cancer that hasn’t spread beyond the prostate. Most surgeons now use a robotic-assisted approach, which allows for smaller incisions and a faster recovery. The procedure typically involves nerve-sparing techniques designed to preserve the nerves responsible for erections and bladder control.
Recovery follows a fairly predictable timeline. You’ll have a catheter for about seven to ten days after surgery. Doctors recommend avoiding strenuous activity and heavy lifting for at least a month. Most men take three to four weeks off work, though those who work from home sometimes return sooner. By one month, daily life starts returning to normal, though some side effects can linger.
The two side effects men worry about most are urinary incontinence and erectile dysfunction. More than 95% of men regain urinary continence within a few months of surgery. Erectile function takes longer to recover. Within one year of a nerve-sparing prostatectomy, about 40 to 50% of men return to their pre-surgery function. By two years, that number reaches 30 to 60%, depending on age, baseline function, and the extent of nerve preservation. These numbers reflect a real trade-off, and it’s worth discussing with your surgeon before making a decision.
Radiation Therapy
Radiation is an alternative to surgery for localized prostate cancer, and for many men it’s equally effective. There are two main types. External beam radiation delivers targeted doses from outside the body over several weeks. Brachytherapy involves placing small radioactive seeds directly into the prostate, which deliver radiation from the inside over a period of weeks or months.
Radiation has its own side effect profile. About 25 to 50% of men who undergo brachytherapy experience erectile dysfunction, and nearly 50% of men who receive standard external beam radiation do as well. These rates are broadly similar to surgery, though the onset is different. With surgery, erectile dysfunction is immediate and may gradually improve. With radiation, erections often remain intact at first but can decline over months or years as the tissue heals and scars. Radiation can also cause bowel irritation, urinary frequency, and fatigue during treatment.
Hormone Therapy for Advanced Cancer
Prostate cancer cells rely on testosterone and other male hormones (androgens) to grow. Hormone therapy, also called androgen deprivation therapy, cuts off that fuel supply. It’s used for cancer that has spread beyond the prostate, cancer that has come back after surgery or radiation, or sometimes alongside radiation to make treatment more effective.
There are several ways to reduce androgen levels. The most direct is surgical removal of the testicles, which drops testosterone in the blood by 90 to 95%. Most men choose drug-based alternatives instead. One class of drugs works by shutting down the brain’s signal that tells the testicles to produce testosterone. These are given as injections every few months or, in one case, as a daily pill. Another class blocks testosterone from attaching to cancer cells, preventing it from fueling growth even when it’s still circulating. Newer versions of these blockers are significantly more powerful than the older ones and are now standard for advanced disease.
A third approach blocks an enzyme the body needs to manufacture testosterone, not just in the testicles but also in the adrenal glands and in the tumor itself. This matters because even after the testicles stop producing testosterone, small amounts are still made elsewhere, and advanced cancers can exploit those tiny amounts.
Hormone therapy comes with its own significant side effects: hot flashes, loss of muscle mass, weight gain, fatigue, mood changes, bone thinning, and reduced sex drive. These effects are manageable but real, and they last as long as treatment continues.
When Cancer Stops Responding to Hormones
Over time, some prostate cancers learn to grow even when testosterone levels are extremely low. This is called castration-resistant prostate cancer, and it requires a different treatment strategy. The newer, more powerful androgen blockers can still work at this stage because they target the cancer’s ability to use androgens in ways the older drugs cannot. Doctors may also add or switch to chemotherapy.
For men whose tumors carry specific genetic mutations, targeted therapies called PARP inhibitors are an option. These drugs exploit a weakness in cancer cells that have faulty DNA repair genes (most commonly BRCA mutations). In clinical trials, men with BRCA mutations who received a PARP inhibitor went roughly 11 months before their cancer progressed, compared to about 6 months on standard treatment. Not every man with advanced prostate cancer has these mutations, so genetic testing of the tumor is an important step.
Chemotherapy: What to Expect
Chemotherapy is typically reserved for metastatic prostate cancer, especially when hormone therapy is no longer controlling the disease. The standard regimen is given as an intravenous infusion once every three weeks, with treatment continuing for up to ten cycles or until the cancer progresses.
Side effects develop on different timescales. In the first hours to days, nausea and changes in taste are common. Over the following days to weeks, fatigue, mouth sores, diarrhea, joint and muscle pain, and skin rashes can appear. The most significant short-term risk is a drop in white blood cells, which increases vulnerability to infections. Over weeks to months, partial hair loss and nail changes are typical. Many men also take a low-dose steroid alongside chemotherapy, which can cause its own issues: trouble sleeping, fluid retention, increased blood sugar, and mood changes.
Choosing Between Treatments
For localized prostate cancer, the choice between active surveillance, surgery, and radiation is rarely straightforward. All three can be appropriate depending on the situation, and survival outcomes for low and intermediate-risk cancers are similar across options. The decision often comes down to which side effects you’re most willing to accept, your age, and how you feel about living with an untreated cancer (even one that’s being closely monitored).
For cancer that has spread, treatment is more sequential. Hormone therapy is usually the foundation, with radiation, chemotherapy, or targeted therapies layered on as needed. The goal shifts from curing the cancer to controlling it for as long as possible while preserving quality of life. Many men live years or even decades with advanced prostate cancer under active treatment, and the number of available therapies has grown substantially in the past ten years.